Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Type1diabetes
Interventions: Mixed Meal Tolerance Test; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pre-Diabetes
Interventions: Aerobic Exercise, Exercise and Diet; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
Interventions: EPI-506; Drug
Lead sponsor: ESSA Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Food Choices
Interventions: Control (QR) Labels, Low Sustainability Labels, Unsustainable Labels, Environmental Harm Labels, High Environmental Harm Labels, High Environmental Cost Labels, Numeric Environmental Cost Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 14,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Evacetrapib, High-fat Meal; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Fasting; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions: DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF; Drug · Combination Product
Lead sponsor: Prism Health North Texas; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Impaired Glucose Tolerance
Interventions: Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity
Interventions: Fast Food Restaurant; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: University of California, Los Angeles, California

Conditions: Metabolic Syndrome
Interventions: Professional nutrition counseling, No professional nutrition counseling; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Insulin aspart, Supplemental insulin aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Part A: Placebo, Nintedanib, GSK3915393; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Healthy Volunteers
Interventions: Lisdexamfetamine Dimesylate; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prediabetes
Interventions: metformin, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: AZD5847, Placebo to AZD5847; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: LY2801653; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Gestational Diabetes
Interventions: GDM screening with 75 g 2 hour GTT, GDM screening with two step approach; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke, Acute
Interventions: BE FAST Educational video, F.A.S.T. Educational Video; Other
Lead sponsor: American Heart Association; Other
Eligibility: 19 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: ZB716, Palbociclib; Drug
Lead sponsor: EnhancedBio USA Inc.; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide 50 mg, Placebo, CCK (Kinevac); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pharmacology
Interventions: Abiraterone: Treatment A, Abiraterone: Treatment B, Abiraterone: Treatment C, Abiraterone: Treatment D; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 35 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsule 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Development of Predictive Biomarkers

Exercise Dose-Response Effects in Prediabetes

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Perceptions of and Reactions to Sustainability Menu Label Designs

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Doravirine and Weight Gain in Antiretroviral Naive

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Comparing Calories at Fast Food Restaurants

Precision Nutrition Impact on Health-Related Behavior Change

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Metformin and Muscle in Insulin-resistant Older Veterans

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

One Step Versus Two Step Approach for Gestational Diabetes Mellitus Screening

F.A.S.T.-BE FAST Stroke Warning Signs Study

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg